Innovation and Incentives: Can Breakthrough Science Survive Market Forces? Harvey Fineberg, Craig Fuller, James Greenwood, Jennifer Jarrett and Richard Klausner speak at The 2007 Aspen Health Forum.
Today we rely largely on for-profit companies to develop new drugs. But do market forces alone bring us the medicines we need? Recognizing that profit drives innovation, we consider public-private partnerships and other models to help sustain promising research - Aspen Institute
Harvey V. Fineberg
Harvey V. Fineberg is President of the Institute of Medicine. He served as Provost of Harvard University from 1997 to 2001, after thirteen years as Dean of the Harvard School of Public Health. Dr. Fineberg helped found and later served as President of the Society for Medical Decision Making. He is the co-author of the books Clinical Decision Analysis, Innovators in Physician Education, and The Epidemic that Never Was, an analysis of the controversial federal immunization program against swine flu in 1976.
He also co-edited several books, and has written numerous articles published in professional journals. He is the recipient of the Joseph W. Mountain Prize and the Wade Hampton Frost Prize. Dr. Fineberg received his bachelor's and professional degrees at Harvard University.
Craig L. Fuller
Craig L. Fuller is Executive Vice President of APCO Worldwide, an independently owned global communication consultancy. Mr. Fuller joined the firm's Washington, D.C., office after holding top positions in the White House, a national trade association, a Fortune 50 corporation and in global consulting firms.
Prior to joining APCO, he established his own consulting firm and previously was President and CEO of the National Association of Chain Drug Stores, where he worked on major health care policy issues with 200 leading retail organizations and 1,000 manufacturers and suppliers to the industry.
At the White House, he served for eight years as Assistant to President Reagan for cabinet affairs and then as Chief of Staff to Vice President George H. W. Bush. Mr. Fuller serves on the board of Stillwater Mining Company and is a director of the United States Chamber of Commerce and the National Chamber Foundation.
James C. Greenwood is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, D.C., which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations. BIO members are involved in the research and development of health care, agricultural, industrial and environmental biotechnology products. Before joining BIO, Mr. Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives.
As a leader on health care issues, he authored numerous bills signed into law including legislation to promote pediatric labeling for pharmaceuticals, reform medical device review and approval, and expand research and establish innovative programs to address traumatic brain injury.
Mr. Greenwood also served six years in the Pennsylvania Senate (1986-1993) and six years in the Pennsylvania General Assembly (1980-86), specializing in health, environment, and children's issues. Mr. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology.
Jennifer Jarrett is a Director in the Health Care Group within the Credit Suisse Investment Banking Department, based in San Francisco. She has more than nine years of investment banking at Credit Suisse focused on biotechnology, with three years of investment banking at Merrill Lynch and Kidder Peabody. Ms. Jarrett received her MBA from Stanford University and her bachelor's from Dartmouth College.
Richard D. Klausner is Managing Partner of The Column Group, a venture capital fund focused on building the next generation of drug discovery and development companies. Dr. Klausner is the former Executive Director for Global Health of the Bill and Melinda Gates Foundation. Prior to that he served as Director of the National Cancer Institute from 1995 to 2001.
Dr. Klausner's research in hematology has been recognized with many awards, including the William Damashek Prize and the Outstanding Investigator Award of the American Federation of Clinical Research. He has served as an adviser to the Presidents of the National Academies for counter-terrorism and as a liaison to the White House Office of Science and Technology Policy. Dr. Klausner is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Robert N. Klein's commitment to advancing medical research originated in his younger son Jordan's diagnosis with Juvenile Diabetes in 2001. In addition, his mother was diagnosed with Alzheimer's two years earlier. In 2002, Klein was a principal negotiator, as a part of a Juvenile Diabetes Research Foundation patient advocate team that worked successfully to pass a $1.5 billion mandatory federal funding bill for an additional five years of Type 1 and Type 2 diabetes supplemental National Institutes of Health research funding.
In 2003, Klein served as the author and Chairman of California's Proposition 71, the $6 billion "California Stem Cell Research and Cures" ballot initiative. Currently he serves as the Chairman of the Governing Board of the California Institute of Regenerative Medicine established by Proposition 71 to manage the peer review, standards, and grant process for the $3 billion in stem cell research funding authorized by the proposed Initiative.